Abstract
Peptides are known to be widely distributed in the body, particularly in the gut and the nervous system. In 1982, the presence of a novel brain peptide, neuropeptide Y (NPY) was reported. Subsequently, it was established that NPY is colocalized and co-released with norepinephrine and is distributed in both the central and the peripheral nervous systems. Other reports have indicated the possible role of NPY as a neuromodulator for the catecholaminergic neurons. Since altered sympathetic activity plays a crucial role in the pathophysiology of congestive heart failure, we examined the role of NPY in the modulation of sympathetic activity in various cardiovascular diseases including congestive heart failure. This review article will provide an insight into the status of the NPY receptor the possible therapeutic targets in congestive heart failure.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
